Contenido principal del artículo

Ana Isabel Sánchez-Marcos
Hospital Universitario de Salamanca. Servicio de Endocrinología. Salamanca. España
España
Biografía
Juan José Corrales-Hernández
Hospital Universitario de Salamanca. Servicio de Endocrinología. Salamanca. España
España
Ana Herrero-Ruiz
Hospital Universitario de Salamanca. Servicio de Endocrinología. Salamanca. España
España
Rosa Ana Iglesias-Lopez
Hospital Universitario de Salamanca. Servicio de Endocrinología. Salamanca. España
España
Mª Teresa Mories-Alvarez
Hospital Universitario de Salamanca. Servicio de Endocrinología. Salamanca. España
España
Vol. 11 Núm. 3 (2020), Artículo de revisión, Páginas 361-368
DOI: https://doi.org/10.14201/orl.21312
Aceptado: ago 24, 2019
Derechos de autor Cómo citar

Resumen


El diagnóstico de hiperparatiroidismo primario en pacientes sin criterio quirúrgico es cada vez más frecuente. Aunque la evidencia de calidad es escasa en algunos casos, cada vez se dispone de más datos que nos permiten conocer el efecto de los distintos fármacos sobre la calcemia, la afectación ósea y renal en pacientes sometidos a ellos durante periodos prolongados de tiempo.
 

Descargas

La descarga de datos todavía no está disponible.

Detalles del artículo

Citas

Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet 2018;391: 168-78.

Bilezikian JP., Brandi ML., Eastell R., Silverberg SJ, Udelsman R., Marcocci C., Potts JT. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop . J Clin Endocrinol Metab. 2014; 99(10): 3561-3569

Caren G. Solomon. Primary hyperparathyroidism. N Engl J Med 2018;379:1050-9.

Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003; 88: 581-7

Eller-Vainicher C, Palmieri S, Cairoli E et al. Protective effect of denosumab on bone in older women with primary hyperthyroidism. J Am Geriatri Soc 2018; 66:518.

Faggiano A, Di Somma C, Ramundo V, et al. Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine 2011;39: 283-7.

Grey AB, Stapleton JP, Evan MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized controlled trial. Ann Intern Med. 1996; 125: 360-8.

Khan A, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY et al. Alendronate in primary hyperparathyroidism: A double-blind, randomized placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89: 3319-25.

Locker FG, Silverberg SJ, Bilezikian JP. Optimal dietary calcium intake in primary hyperparathyroidism. Am J Med 1997; 102: 543.

Marcocci C, Bollerslev J, Khan AA, Shoback DM. Medical management of primary hyperparathyroidism: proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2014;99(10): 3607–3618

Muñoz-Torres M., García-Martín A. Hiperparatiroidismo primario. Med Clin (Barc.).2018;150(6):226-232

Muñoz-Torres M., Jodar-Gimeno E., Reyes-García R., Martínez-Diaz-Guerra G, Amado JA., Gaztambide S et al. Results from a national survey on the management of primary hyperparathyroidism. J Bone Mineral Res. 2012;35:957-63.

Nilsson I L. Primary hypreparathyroidism: should surgery be performed on all patients? Current evidence and residual uncertainties. J Intern Med. 2019;285:149-164.

Orr-Walker BJ, Evans MC, Clearwater JM, et al. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four year follow-up and comparison with healthy postmenopausal women. Ann Intern Med 2000; 160: 2161.

Peacock M, Bilezikian JP, Klassen PS, et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005;90:135-41.

Rolighed L, Renjmark L, Sikjaer T, Heickendorff L, Vestegaard P, Mosekilde L et al. Vitamin D treatment in primary hyperparathyroidism: A randomized placebo, controlled trial. J Clin Endocrinol Metab. 2014; 99:1072-80.

Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S,. Effects of oral alendronate in elderly patients with ospteoporosis and mild primary hyperparathyroidism. J Bone miner Res. 2001; 16:113-9.

Rubin MR, Bilezikian JP, McMahon DJ et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008; 93:3462-70.

Sankaran S, Gamble G, Bolland M, Reid IR, Grey A. Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A Meta-Analysis . J Clin Endocrinol Metab. 2010; 95(4):1653–1662 .

Schwarz P, Body JJ, Cáp J, Hofbauer LC, Farouk M, Gessl A et al. The PRIMARA study: A prospective, descriptive, obsrvational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. Eur J Endocrinol.2014;171:727-35.

Tsvetov G, Hirsch D, Shimon I et al. Thiazide treatment in primary hyperparathyroidism - a new indication for an old medication? J Clin Endocrinol Metab 2017; 102: 1270–6.